|
Real-world evidence highlights the urgent need to act on the growing global burden of chronic kidney disease
|
16 June 2023 |
|
AstraZeneca announces agreement with Quell Therapeutics to develop, manufacture and commercialise engineered T-regulatory cell therapies for autoimmune diseases
|
12 June 2023 |
|
Update to contractual arrangements between AstraZeneca, Swedish Orphan Biovitrum AB and Sanofi
|
12 April 2023 |
|
AstraZeneca launches call for entries to the 2023 global R&D Postdoctoral Challenge
|
15 March 2023 |
|
AstraZeneca enters license agreement with KYM Biosciences for CMG901, a Claudin-18.2 antibody drug conjugate
|
23 February 2023 |
|
Acquisition of Neogene Therapeutics completed
|
16 January 2023 |
|
AstraZeneca to acquire CinCor Pharma to strengthen cardiorenal pipeline
|
09 January 2023 |
|
AstraZeneca to acquire Neogene Therapeutics, accelerating ambition in Oncology cell therapy
|
29 November 2022 |
|
Evusheld long-acting antibody combination approved in the EU for the treatment of COVID-19
|
29 September 2022 |
|
AstraZeneca to acquire TeneoTwo and its clinical-stage T-cell engager
|
21 July 2022 |